Ryan McDonald | Authors

First-line Ribociclib-AI Combo Associated with Better Symptom-Related QOL Vs Abemaciclib-AI in HR+/HER2− Advanced Breast Cancer

June 06, 2022

Results of a matching-adjusted indirect comparison study showed that patients with HR-positive/HER2–negative advanced breast cancer treated with ribociclib and an aromatase inhibitor were more likely to have better symptom-related quality of life than patients who received abemaciclib and an aromatase inhibitor.

Preliminary Results Show Second-line Lurbinectedin Plus Pembrolizumab Safe, Effective in Relapsed SCLC

June 06, 2022

Preliminary findings of data from the phase 1/2 LUPER study demonstrate that treatment with lurbinectedin combined with pembrolizumab elicits promising efficacy in patients with metastatic small-cell lung cancer that has failed to respond to chemotherapy.

Long-Term Follow-Up Continues to Show Acalabrutinib-Based Regimens Superior to Obinutuzumab Plus Chemo in Treatment-Naïve CLL

June 04, 2022

At approximately 5 years of follow-up, findings from the phase 3 ELEVATE-TN study show that treatment outcomes are more favorable with acalabrutinib with or without obinutuzumab compared with obinutuzumab and chlorambucil in treatment-naïve chronic lymphocytic leukemia.

Despite Increased Use of Telemedicine for Cancer Care During COVID-19, Disparities Persist

May 26, 2022

The findings of this retrospective study of more than 25,000 patients with cancer newly diagnosed during the COVID-19 pandemic highlight a need to reduce the inequities in telemedicine use for cancer care, according to the study’s lead author.